Consolidated balance sheet as at December 31
|
in CHF 1 000 |
|
Notes |
|
2022 |
|
2021 |
|
Current assets |
|
|
|
|
|
|
|
Cash and cash equivalents |
|
|
|
1 948 |
|
2 835 |
|
Securities |
|
4 |
|
3 051 349 |
|
3 641 112 |
|
Other assets |
|
|
|
92 |
|
135 |
|
|
|
|
|
3 053 389 |
|
3 644 082 |
|
Total assets |
|
|
|
3 053 389 |
|
3 644 082 |
|
|
|
|
|
|
|
|
|
Current liabilities |
|
|
|
|
|
|
|
Short-term borrowings from banks |
|
5 |
|
363 000 |
|
355 000 |
|
Other short-term liabilities |
|
6 |
|
4 143 |
|
5 431 |
|
Tax liabilities |
|
|
|
111 |
|
158 |
|
|
|
|
|
367 254 |
|
360 589 |
|
Total liabilities |
|
|
|
367 254 |
|
360 589 |
|
|
|
|
|
|
|
|
|
Shareholders' equity |
|
|
|
|
|
|
|
Share capital |
|
7 |
|
11 080 |
|
11 080 |
|
Treasury shares |
|
7 |
|
(36 508) |
|
(9 205) |
|
Retained earnings |
|
7 |
|
2 711 563 |
|
3 281 618 |
|
|
|
|
|
2 686 135 |
|
3 283 493 |
|
Total liabilities and shareholders' equity |
|
|
|
3 053 389 |
|
3 644 082 |
|
|
|
|
|
|
|
|
|
Net asset value per share in CHF |
|
|
|
49.00 |
|
59.40 |
The notes are an integral part of the consolidated financial statements.
The consolidated financial statements were approved by the Board of Directors of BB Biotech AG on February 14, 2023.